Aura Biosciences, Inc. SEC filings AURA
Aura Biosciences, Inc. has 381 filings in SEC EDGAR's recent list, going back to Sep 21, 2010. Its latest annual report, Form ARS, was filed on Apr 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, exit or restructuring costs, officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Jun 29, 2026 | Aug 5, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 17, 2026 | Aug 5, 2026 |
| DEFA14A | Additional proxy material | May 4, 2026 | — |
| DEFA14A | Additional proxy material | Apr 20, 2026 | — |
| DEF 14A | Proxy statement | Apr 20, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Jun 14, 2024 | — |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 20, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 25, 2023 | Jun 7, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 15, 2022 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1501796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.